Aribiolab아리바이오랩
261780 · KOSDAQ · ₩261780 · 아리바이오랩
₩3,400▼ ₩185 (5.16%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩159M | ₩371M | ₩294M | ₩179M | ₩500M |
| Cost of sales | ₩15M | ₩24M | ₩35M | ₩19M | ₩0 |
| Gross profit | ₩144M | ₩347M | ₩260M | ₩160M | ₩500M |
| Operating income | −₩14B | −₩7.7B | −₩6.4B | −₩6.5B | −₩6.1B |
| Net income | −₩16B | −₩10B | −₩1.7B | −₩6.7B | −₩18B |
| Net income to shareholders | −₩16B | −₩10B | −₩1.7B | −₩6.7B | −₩18B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩30B | ₩47B | ₩45B | ₩61B | ₩65B |
| Current assets | ₩27B | ₩45B | ₩42B | ₩59B | ₩62B |
| Cash and equivalents | ₩9.8B | ₩10B | ₩5.9B | ₩2.4B | ₩4B |
| Total liabilities | ₩18B | ₩20B | ₩9.7B | ₩28B | ₩26B |
| Current liabilities | ₩16B | ₩9.6B | ₩810M | ₩27B | ₩25B |
| Borrowings | — | ₩4.6B | ₩4B | ₩23B | ₩21B |
| Total equity | ₩12B | ₩28B | ₩35B | ₩33B | ₩40B |
| Shareholders' equity | ₩12B | ₩28B | ₩35B | ₩33B | ₩40B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩11B | −₩8.1B | −₩5.3B | −₩5.2B | −₩4.7B |
| Capital spending | ₩117M | ₩179M | ₩279M | ₩447M | ₩680M |
| Free cash flow | −₩11B | −₩8.3B | −₩5.6B | −₩5.6B | −₩5.4B |
Consolidated where available. Amounts in won.
Also known as: Aribiolab / 아리바이오랩 / 261780 / KRX:261780
Source: KRX statistical information